Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

  • June 24, 2026

Share

Clinical Report: Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

Overview

A new clinical trial is investigating the addition of low-dose oral chemotherapy (cyclophosphamide) to standard immunotherapy for melanoma patients who have progressed after first-line treatment.

Background

Melanoma treatment has evolved significantly with the advent of immunotherapy; however, many patients develop resistance to these therapies over time. The exploration of combining traditional chemotherapy with immunotherapy is being studied.

Data Highlights

No numerical data or trial results are provided in the source material.

Key Findings

  • The trial is led by Dr. Warren Chow and sponsored by the UC Irvine Anti-Cancer Challenge.
  • It focuses on patients who have progressed on first-line immunotherapy for melanoma.
  • The study aims to evaluate the efficacy of adding low-dose cyclophosphamide to standard immunotherapy.
  • Insights from this trial are expected to be available by ASCO 2027.
  • The approach seeks to address the challenge of resistance to immune checkpoint inhibitors.

Clinical Implications

This trial may provide insights into treatment strategies for melanoma patients who have limited options after failing first-line therapies.

Conclusion

The ongoing clinical trial is focused on addressing treatment resistance in melanoma.

Related Resources & Content

  1. UCI Health, UCI Health, 2023 -- Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma
  2. The ASCO Post — Oral Metronomic Chemotherapy Plus Ultra-Low-Dose Immunotherapy Improves Survival in Advanced Head and Neck Cancer
  3. The ASCO Post — Study Suggests Lack of Benefit With the Addition of Immune Checkpoint Inhibition to Chemotherapy in Low PD-L1–Expressing Gastric or Esophageal Adenocarcinoma
  4. Stat News — Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
  5. the asco post — Four-Drug Induction Regimen Under Study in Advanced Melanoma With BRAF Mutation
  6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
  7. Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy - PMC
  8. Study Details | NCT06771544 | Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma | ClinicalTrials.gov

Original Source(s)

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

  • June 24, 2026

Related Content

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min
Beyond classical boundaries: rethinking ICU access in acute leukemia

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

  • by

  • September 24, 2026

  • 11 min